Skip to content
Open in App
Abionyx Pharma SA logo

Abionyx Pharma SA

web2

ABIONYX Pharma is a French biotechnology company developing apoA-I-based therapies and biologic...

Symbol ยท ABNX
Company profile

About

ABIONYX Pharma is a French biotechnology company developing apoA-I-based therapies and biologic candidates for severe inflammatory, renal, and ophthalmological conditions with limited treatment options. Its principal asset, CER-001, is an engineered high-density lipoprotein-like particle containing recombinant apolipoprotein A-I and phospholipids, designed to support reverse lipid transport and removal of excess cholesterol. The company is developing CER-001 for severe inflammation and sepsis and is structuring its bioproduction chain through manufacturing partnerships. Its research also addresses renal and ophthalmological diseases, while its drug candidates remain subject to development and regulatory requirements.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

ExchangeParisPrimary symbol: ABNX
Expert coverage

Abionyx Pharma SA profile.

Orbitrum research

Expert coverage

No published expert evaluations are available for this project yet.

Orbitrum Academy

Learn how to read a project assessment